Proxy Advisors Back Boralex’s $37.25 Per Share Sale to Brookfield-Caisse Consortium
Event summary
- Boralex shareholders to receive $37.25 per share in cash under the arrangement with Brookfield-Caisse consortium.
- ISS and Glass Lewis recommend voting FOR the deal, citing strategic review process and premium valuation.
- Glass Lewis highlights valuation at multi-year high and upper range of formal valuation.
- Shareholder meeting scheduled for June 4, 2026, with proxy deadline on June 2, 2026.
- Boralex has obtained Competition Act Approval and HSR Clearance, with other regulatory approvals pending.
The big picture
The endorsement from leading proxy advisors strengthens the case for Boralex’s sale to the Brookfield-Caisse consortium, highlighting the strategic and financial rationale behind the deal. This transaction reflects broader trends in the renewable energy sector, where consolidation and private equity investment are reshaping the competitive landscape. The $37.25 per share offer represents a premium valuation, underscoring the strategic value of Boralex’s assets in the infrastructure space.
What we're watching
- Regulatory Approvals
- Whether Boralex secures remaining regulatory approvals ahead of the June 4 shareholder meeting.
- Shareholder Support
- The level of shareholder approval given the positive recommendations from ISS and Glass Lewis.
- Integration Challenges
- How the transition under new ownership by Brookfield and Caisse will impact Boralex’s operations.
Related topics